For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
Scope of the Report:
PARP (Poly ADP-Ribose Polymerase) Inhibitor first approval in United States in 2014. And in the last several years, global market (value) of PARP (Poly ADP-Ribose Polymerase) Inhibitor developed rapidly, with an average growth rate of 133.8% during 2015 to 2018.
The classification of PARP (Poly ADP-Ribose Polymerase) Inhibitor includes Lynparza, Zejula, Rubraca, Talzenna and other. Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.
The worldwide market for PARP (Poly ADP-Ribose Polymerase) Inhibitor is expected to grow at a CAGR of roughly 31.4% over the next five years, will reach 4855 million US$ in 2024, from 1239.9 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the PARP (Poly ADP-Ribose Polymerase) Inhibitor in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- AstraZeneca
- Tesaro
- Merck & Co
- Clovis Oncology
- Pfizer
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Lynparza
- Zejula
- Rubraca
- Talzenna
- Other
Market Segment by Applications, can be divided into
- Ovarian Cancer
- Breast Cancer
- Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, with price, sales, revenue and global market share of PARP (Poly ADP-Ribose Polymerase) Inhibitor in 2017 and 2018.
Chapter 3, the PARP (Poly ADP-Ribose Polymerase) Inhibitor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PARP (Poly ADP-Ribose Polymerase) Inhibitor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, PARP (Poly ADP-Ribose Polymerase) Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor sales channel, distributors, customers, research findings and conclusion, appendix and data source.